BERNAT QUERALT MERINO

Cirurgía General y Digestiva , Oncología de Precisión de Girona , Enfermedades Digestivas y Microbiota

Dámaso E, Canet-Hermida J, Vargas-Parra G, Velasco À, Marín F, Darder E, Del Valle J, Fernández A, IZQUIERDO, A., Mateu G, Oliveras G, Escribano C, Piñol V, Uchima HI, Soto JL, Hitchins M, Farrés R, Lázaro C, Queralt B, Brunet J, Capellá G, Pineda M

Highly sensitive <i>MLH1</i> methylation analysis in blood identifies a cancer patient with low-level mosaic <i>MLH1</i> epimutation

CLINICAL EPIGENETICS, 2019, 11, 171-171 dx.doi.org/10.1186/s13148-019-0762-6

Metabolismo y Cáncer , Oncología de Precisión de Girona

Cuyàs E, Queralt B, Martin-Castillo B, Bosch-Barrera J, Menendez JA

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.

ONCOLOGY REPORTS, 2017, 38, 263-270 dx.doi.org/10.3892/or.2017.5682

Metabolismo y Cáncer , Oncología de Precisión de Girona

Bosch-Barrera J, Queralt B, Menendez JA

Targeting STAT3 with silibinin to improve cancer therapeutics.

CANCER TREATMENT REVIEWS, 2017, 58, 61-69 dx.doi.org/10.1016/j.ctrv.2017.06.003

Metabolismo y Cáncer , Cirurgía General y Digestiva , Oncología de Precisión de Girona , Oncología Radioterápica y Física Médica de Girona

Puig-Costa M, Codina-Cazador A, Cortés-Pastoret E, Oliveras-Ferraros C, Cufí S, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Corominas-Faja B, Cuyàs E, Ortiz R, Lopez-Bonet E, Queralt B, Guardeño R, Martin-Castillo B, Roig J, Joven J, Menendez JA

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Oncotarget, 2014, 5, 1942-1954 dx.doi.org/10.18632/oncotarget.1879

Cirurgía General y Digestiva , Oncología de Precisión de Girona

Vera R, Gomez Dorronsoro M, Lopez-Ben S, Viudez A, Queralt B, Hernandez I, Ortiz-Duran MR, Zazpe C, Soriano J, Amat I, Herrera Cabezón J, Diaz E, Codina-Barreras A, Hernandez-Yagüe X, Quera A, Figueras J

Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16, 739-745 dx.doi.org/10.1007/s12094-013-1142-x

Metabolismo y Cáncer , Oncología de Precisión de Girona

Oliveras-Ferraros C, Massaguer Vall-Llovera A, Vazquez-Martin A, Salip DC, Queralt B, Cufí S, Martin-Castillo B, Bosch-Barrera J, Brunet J, De Llorens R, Menendez JA

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.

ONCOLOGY REPORTS, 2012, 27, 1887-1892 dx.doi.org/10.3892/or.2012.1732

Metabolismo y Cáncer , Oncología de Precisión de Girona

Oliveras-Ferraros C, Massaguer Vall-Llovera A, Salip DC, Vazquez-Martin A, Cufí S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.

INVESTIGATIONAL NEW DRUGS, 2012, 30, 846-852 dx.doi.org/10.1007/s10637-010-9612-2

Metabolismo y Cáncer , Oncología de Precisión de Girona

Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39, 1455-1479 dx.doi.org/10.3892/ijo.2011.1155

Metabolismo y Cáncer , Oncología de Precisión de Girona

Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112, 10-29 dx.doi.org/10.1002/jcb.22952

Directori

Publicacions

Highly sensitive <i>MLH1</i> methylation analysis in blood identifies a cancer patient with low-level mosaic <i>MLH1</i> epimutation

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.

Targeting STAT3 with silibinin to improve cancer therapeutics.

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

Formulari de contacte

Conoce el IDIBGI!